ストックスクリーナーアプリを入手
4.97
9.23%
0.42
アフターアワーズ：
4.85
-0.12
-2.41%
前日終値:
$4.55
開ける：
$4.755
24時間の取引高:
16,510
Relative Volume:
0.33
時価総額：
$4.72M
収益：
-
当期純損益:
$-40.36M
株価収益率:
-0.1022
EPS:
-48.648
ネットキャッシュフロー:
$-21.40M
1週間 パフォーマンス:
+5.74%
1か月 パフォーマンス:
-7.79%
6か月 パフォーマンス:
-28.59%
1年 パフォーマンス:
-39.46%
1日の値動き範囲:
$4.5675
$5.17
1週間の範囲:
$4.0701
$5.30
52週間の値動き範囲:
$3.82
$20.99
Transcode Therapeutics Inc Stock (RNAZ) Company Profile
Compare RNAZ vs VRTX, REGN, ARGX, ALNY, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
RNAZ
Transcode Therapeutics Inc
|
4.97 | 4.32M | 0 | -40.36M | -21.40M | -48.65 |
VRTX
Vertex Pharmaceuticals Inc
|
491.34 | 121.87B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
632.90 | 65.01B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
887.18 | 55.26B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
291.37 | 39.14B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
182.08 | 37.88B | 742.00K | -1.37B | -1.07B | -7.0731 |
Transcode Therapeutics Inc (RNAZ) 最新ニュース
TransCode Therapeutics, Inc. Actuals & Estimates (BOATS:RNAZ) - TradingView
RNAZ Technical Analysis | Trend, Signals & Chart Patterns - ChartMill
Discipline and Rules-Based Execution in RNAZ Response - Stock Traders Daily
TransCode Highlights Progress of Lead RNA Cancer Therapeutic - TipRanks
Transcript : TransCode Therapeutics, Inc.Special Call - marketscreener.com
TransCode Therapeutics posts investor presentation detailing Phase 1a safety, Phase 2a plan and $12.8M cash - TradingView
TransCode Therapeutics (NASDAQ: RNAZ) furnishes new investor presentation via Form 8-K - Stock Titan
Transcode Therapeutics Inc (RNAZ) Valuation: PE, PB & Fair Value Analysis - TradingKey
Transcode Therapeutics Inc (RNAZ) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Transcode Therapeutics Inc (RNAZ) Institutional Confidence - TradingKey
Transcode Therapeutics Inc (RNAZ) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Transcode Therapeutics Inc (RNAZ) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Transcode Therapeutics Inc (RNAZ) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Transcode Therapeutics Inc (RNAZ) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Transcode Therapeutics Inc (RNAZ) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Transcode Therapeutics Inc (RNAZ) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
TransCode Therapeutics (RNAZ) Rallies 3.27% as Biotech Stock Tests Key ResistanceFactor Crowding - newsline.com
RNAZ Technical Analysis & Stock Price Forecast - Intellectia AI
TransCode Therapeutics (RNAZ) Q4 2024 Earnings: Wider-Than-Expected Loss Amid No RevenueAnalyst Earnings Estimate - newsline.com
Daily Brief Health Care: Parabilis Medicines, Integral Diagnostics, Healthequity Inc, ICON PLC, KT Medical Service, Leong Guan Holdings, Oramed Pharmaceuticals , Otsuka Holdings, Crism Therapeutics, TransCode Therapeutics and more - Smartkarma
Inside a new colorectal cancer trial: TransCode’s June 18 webcast with Harvard oncologist - Stock Titan
RNAZ: Introducing RNA Therapeutics - Yahoo Finance
TransCode Therapeutics (RNAZ) Q4 2024 Earnings: Wider-Than-Expected Loss Amid Continued Pipeline DevelopmentMid-Term Outlook - newsline.com
RNAZ Q4 2024 Earnings: Wider-Than-Expected Loss Amid Pre-Revenue Clinical DevelopmentForward EPS Estimate - newsline.com
RNAZ Q4 2024 Earnings: Wider-than-expected loss amid pre-revenue stageNet Profit Margin - newsline.com
EXCLUSIVE: TransCode's RNA Therapeutic Achieves 64% Stable Disease Rate In Colorectal Cancer Phase 1 Study - Sahm
Exclusive: TransCode's RNA therapeutic achieves 64% stable disease rate in colorectal cancer phase 1 study - MSN
TransCode Therapeutics (RNAZ) Advances to Phase 2a Following Pos - GuruFocus
RNAZ | TransCode Therapeutics, Inc. Common Executive Compensation - Quiver Quantitative
TransCode Therapeutics Advances TTX-MC138 After Positive Phase 1a - TipRanks
TransCode completes phase 1a trial of cancer drug TTX-MC138 By Investing.com - Investing.com Australia
TransCode Therapeutics (RNAZ) sees clean Phase 1a safety, 64% stable disease with TTX-MC138 - Stock Titan
TransCode Therapeutics Successfully Completes Phase 1a Clinical Trial, Reports Safety and Stabilization Data for TTX-MC138 in Metastatic Cancer - PR Newswire
TRANSCODE THERAPEUTICSPHASE 1A TRIAL MEETS SAFETY ENDPOINT WITH NO DOSE-LIMITING TOXICITIES - Moomoo
TransCode Therapeutics (RNAZ) proxy bundles big equity, financing and director votes - Stock Titan
TransCode Therapeutics sets date for 2026 annual meeting and proposal deadlines - Investing.com Nigeria
TransCode Sets Key Deadlines for 2026 Shareholder Meeting - TipRanks
TransCode Therapeutics, Inc. Files Form 8-K with NASDAQ Listing and Company Details (RNAZ) - Minichart
TransCode Therapeutics sets date for 2026 annual meeting and proposal deadlines By Investing.com - Investing.com South Africa
TransCode Therapeutics (RNAZ) sets July 2, 2026 annual meeting and June 11 proposal cutoff - Stock Titan
(RNAZ) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
RNAZ Stock Price, Quote & Chart | TRANSCODE THERAPEUTICS INC (NASDAQ:RNAZ) - ChartMill
TransCode Therapeutics Initiates Phase 2a Trial of TTX-MC138 in Colorectal Cancer Patients with Minimal Residual Disease - citybuzz -
TransCode initiates phase 2a trial for colorectal cancer drug By Investing.com - Investing.com Australia
TransCode Therapeutics Initiates Phase 2a Clinical Trial With TTX-MC138 in Patients With CtDNA Positive Colorectal Cancer - Moomoo
TransCode Therapeutics Initiates Phase 2a Clinical Trial with TTX-MC138 in Patients with ctDNA Positive Colorectal Cancer - PR Newswire
TransCode Therapeutics (RNAZ) Drops 10.66%: Support at $5.3 Faces Critical Test After Sharp DeclineCTA Positioning - The Legal Advocate
TransCode Therapeutics Files 8-K/A Detailing Nasdaq Compliance Plan and Soliciting Material Disclosure - Minichart
Nasdaq warns TransCode (NASDAQ: RNAZ) on equity shortfall and delisting risk - Stock Titan
TransCode Therapeutics (RNAZ) Gains Over 2% as Biotech Stock Tests Key Resistance LevelsStop Hunt - newsline.com
TransCode Therapeutics Receives Nasdaq Listing Deficiency Notice - TipRanks
Transcode Therapeutics Inc (RNAZ) 財務データ
収益
当期純利益
現金流量
EPS
1.36%
大文字化:
|
ボリューム (24 時間):